THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth today announced the launch of its new blog, Targeting Cancer. The blog shares expert perspectives on the fast-moving changes in cancer treatment and engages in a broader conversation about the challenges physicians and patients face in battling cancer.
Currently, 75 percent of cancer treatments don’t work1: Only a small percentage of patients are likely to respond to any particular cancer treatment, because every patient’s cancer is unique to their own genetic makeup.
New, more targeted cancer treatments are coming online that promise a revolution in cancer care. But to make effective use of these treatments requires a detailed understanding of how the subtle differences in a patient’s genetic and molecular makeup drive the progression and treatment of cancer.
The Targeting Cancer blog will cover topics such as:
- Treating cancer -- on how targeted cancer care is leading to greater clinical insight and better treatment decisions
- Cancer genetics -- as our understanding of how a patient’s genes drive the progression and treatment of cancer continues to evolve
- Bioinformatics -- technology that transforms the terabytes of genetic data into clinical insight
- Personalized medicine -- because personalized, precision medicine requires more than knowing the genetic makeup of a patient’s tumor
Contributors to MolecularHealth's Targeting Cancer blog include seasoned business leaders, entrepreneurs, oncologists, pathologists, scientists, and technologists. The blog’s initial authors include:
- Lloyd Everson, M.D., Chief Executive Officer of MolecularHealth
- David Jackson, Ph.D., Chief Scientific Officer of MolecularHealth
- Shelly Gunn, M.D., Ph.D., Chief Medical Officer of MolecularHealth
- Laura Housman, Chief Commercial Officer of MolecularHealth
- Alexander Picker, Ph.D., Senior Director of Product Management at MolecularHealth
_______________________
1 Source: Brian B. Spear, Margo
Heath-Chiozzi, Jeffrey Huff, “Clinical Trends in Molecular Medicine,”
Volume 7, Issue 5, 1 May 2001, pp. 201 – 204
ABOUT MOLECULARHEALTH
MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has a CLIA-certified NGS lab and headquarters in The Woodlands, Texas, as well as locations in Boston, Mass. and Heidelberg, Germany.
Website: www.molecularhealth.com
Targeting
Cancer Blog: blog.molecularhealth.com
Twitter:
www.twitter.com/molecularhealth
LinkedIn:
www.linkedin.com/company/molecularhealth
YouTube:
www.youtube.com/user/MolecularHealthInc
